Sentence examples for malaria were randomized from inspiring English sources

Patients aged 6 months to 10 years with uncomplicated falciparum malaria were randomized to therapy and followed for 42 days.

In ARC2, patients with uncomplicated falciparum malaria were randomized to receive one of three artesunate dosing regimens: 2, 4, or 6 mg/kg/day for 7 days.

In ARC1, patients with uncomplicated P. falciparum malaria were randomized in a 2∶1 ratio to receive 7 days of artesunate (4 mg/kg/day) or quinine (30 mg/kg/day) plus tetracycline (25 mg/kg/day) for 7 days.

Adult patients with uncomplicated P. falciparum malaria were randomized into one of three 7-day AS monotherapy regimens: 2, 4 or 6 mg/kg/day (total dose 14, 28 and 42 mg/kg).

Patients with microscopically confirmed uncomplicated P. falciparum malaria were randomized into one of the four treatment groups: Chloroquine (CQ), Amodiaquine (AQ), Sulfadoxine-Pyrimethamine association (SP) and Artesunate-Amodiaquine combination (ASAQ).

1372 patients (≥1 to <15 years old, median age 3 years) with acute uncomplicated P. falciparum malaria were randomized (2∶1) to receive CDA 2/2.5/4 mg/kg once daily for three days (N = 914) or six-doses of AL over three days (N = 458).

G6PD normal patients diagnosed with vivax malaria are randomized to receive either 7 or 14 days high dose primaquine or placebo.

Efficacy data were evaluated with an intention-to-treat analysis including all patients with falciparum malaria who were randomized to study drug therapy [12].

Eighteen malaria-naive adults aged 19 39 years were randomized in a 1∶1∶1 ratio to receive 1, 3 or 5 bites of A. stephensi mosquitoes infected with P. falciparum (Figure 1).

Thirty malaria-naive adults aged 18 45 years were randomized into one of six groups to receive a total dose of 1 × 10 (four groups) or 5 × 10 PfSPZ (two groups) of PfSPZ Challenge.

Participants were randomized to receive three doses of either RTS,S/AS02A candidate malaria vaccine or a control vaccine.